UPDATE: Jefferies Downgrades HealthSouth Corporation to Hold on Regulatory Headwinds
Jefferies lowered its HealthSouth Corporation (NYSE: HLS) rating from Buy to Hold and reduced its price target from $25 to $23.
Jefferies noted, "HLS's strong Q2 performance and raised guidance was impressive, but we recommend taking advantage of stock strength to lighten long positions, fearing that IRF reimbursement could get greater scrutiny later this year when legislators look for funding offsets to another doc fix and deficit reduction."
HealthSouth Corporation closed at $22.93 on Thursday.
Latest Ratings for HLS
|Jan 2017||PiperJaffray||Initiates Coverage On||Neutral|
|Aug 2016||SunTrust Robinson Humphrey||Maintains||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.